Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases.

Takenaka K, Komiya Y, Ota M, Yamazaki H, Nagasaka K.

Mod Rheumatol. 2013 Jul;23(4):752-8. doi: 10.1007/s10165-012-0730-x. Epub 2012 Aug 22.

PMID:
22907597
2.
3.

Twice weekly Pneumocystis jiroveci pneumonia prophylaxis with trimethoprim-sulfamethoxazole in pediatric patients with acute lymphoblastic leukemia.

Agrawal AK, Chang PP, Feusner J.

J Pediatr Hematol Oncol. 2011 Jan;33(1):e1-4. doi: 10.1097/MPH.0b013e3181fd6fca.

PMID:
21102354
4.

Preventive effect of sulfamethoxasole-trimethoprim on Pneumocystis jiroveci pneumonia in patients with interstitial pneumonia.

Enomoto T, Azuma A, Matsumoto A, Nei T, Fujita K, Hattori K, Saito Y, Abe S, Usuki J, Kudoh S.

Intern Med. 2008;47(1):15-20. Epub 2008 Jan 1.

6.

Clindamycin-primaquine for pneumocystis jiroveci pneumonia in renal transplant patients.

Nickel P, Schürmann M, Albrecht H, Schindler R, Budde K, Westhoff T, Millward J, Suttorp N, Reinke P, Schürmann D.

Infection. 2014 Dec;42(6):981-9. doi: 10.1007/s15010-014-0660-y. Epub 2014 Aug 29.

PMID:
25168263
8.

Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim-sulfamethoxazole: lessons from an observational cohort study.

Creemers-Schild D, Kroon FP, Kuijper EJ, de Boer MG.

Infection. 2016 Jun;44(3):291-9. doi: 10.1007/s15010-015-0851-1. Epub 2015 Oct 15.

9.

Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia.

Yang JJ, Huang CH, Liu CE, Tang HJ, Yang CJ, Lee YC, Lee KY, Tsai MS, Lin SW, Chen YH, Lu PL, Hung CC.

PLoS One. 2014 Sep 3;9(9):e106141. doi: 10.1371/journal.pone.0106141. eCollection 2014.

11.

Retrospective investigation of side effects and prognoses of moderate-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia that developed in patients with autoimmune diseases.

Shibata T, Tonooka K, Tsuchida K, Mitomi H, Shibata T, Katsuyama N.

Nihon Rinsho Meneki Gakkai Kaishi. 2016;39(3):213-8. doi: 10.2177/jsci.39.213.

12.

Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268.

Para MF, Finkelstein D, Becker S, Dohn M, Walawander A, Black JR.

J Acquir Immune Defic Syndr. 2000 Aug 1;24(4):337-43.

PMID:
11015150
13.

Treatment of Pneumocystis carinii pneumonia in patients with AIDS.

Wordell CJ, Hauptman SP.

Clin Pharm. 1988 Jul;7(7):514-27.

PMID:
3138063
14.

Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for pneumocystis pneumonia: a pilot study in mice.

Lobo ML, Esteves F, de Sousa B, Cardoso F, Cushion MT, Antunes F, Matos O.

PLoS One. 2013 Aug 5;8(8):e70619. doi: 10.1371/journal.pone.0070619. Print 2013.

15.

Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia.

Levinsen M, Shabaneh D, Bohnstedt C, Harila-Saari A, Jonsson OG, Kanerva J, Lindblom A, Lund B, Andersen EW, Schmiegelow K; Nordic Society of Paediatric Haematology and Oncology (NOPHO)..

Eur J Haematol. 2012 Jan;88(1):78-86. doi: 10.1111/j.1600-0609.2011.01695.x. Epub 2011 Oct 2.

PMID:
21854453
16.

Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial.

Utsunomiya M, Dobashi H, Odani T, Saito K, Yokogawa N, Nagasaka K, Takenaka K, Soejima M, Sugihara T, Hagiyama H, Hirata S, Matsui K, Nonomura Y, Kondo M, Suzuki F, Tomita M, Kihara M, Yokoyama W, Hirano F, Yamazaki H, Sakai R, Nanki T, Koike R, Kohsaka H, Miyasaka N, Harigai M.

Arthritis Res Ther. 2017 Jan 18;19(1):7. doi: 10.1186/s13075-016-1206-8.

17.

Renal Insufficiency in Concert with Renin-angiotensin-aldosterone Inhibition Is a Major Risk Factor for Hyperkalemia Associated with Low-dose Trimethoprim-sulfamethoxazole in Adults.

Higashioka K, Niiro H, Yoshida K, Oryoji K, Kamada K, Mizuki S, Yokota E.

Intern Med. 2016;55(5):467-71. doi: 10.2169/internalmedicine.55.5697. Epub 2016 Mar 1.

18.

Single-day trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis pneumonia in children with cancer.

Caselli D, Petris MG, Rondelli R, Carraro F, Colombini A, Muggeo P, Ziino O, Melchionda F, Russo G, Pierani P, Soncini E, DeSantis R, Zanazzo G, Barone A, Cesaro S, Cellini M, Mura R, Milano GM, Meazza C, Cicalese MP, Tropia S, De Masi S, Castagnola E, Aricò M; Infectious Diseases Working Group of the Associazione Italiana Ematologia Oncologia Pediatrica..

J Pediatr. 2014 Feb;164(2):389-92.e1. doi: 10.1016/j.jpeds.2013.10.021. Epub 2013 Nov 16.

PMID:
24252793
19.
20.

[Pneumocystis jiroveci pneumonia as a complication of glucocorticoid therapy for interstitial pneumonia].

Enomoto T, Azuma A, Matsumoto A, Nei T, Hiramatsu K, Abe S, Usuki J, Kudoh S.

Nihon Kokyuki Gakkai Zasshi. 2005 Dec;43(12):725-30. Japanese.

PMID:
16457333

Supplemental Content

Support Center